LNCR
MCID: LNG032
MIFTS: 99

Lung Cancer (LNCR)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 58 12 77 26 76 30 6 44 3 15
Non-Small Cell Lung Cancer 12 77 38 30 6 15
Non-Small Cell Lung Carcinoma 39 12 15 17 74
Lung Carcinoma 12 56 15 17
Lung Cancer, Protection Against 58 30 6
Nonsmall Cell Lung Cancer 58 76 13
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 58 13
Lung Cancer, Susceptibility to 58 6
Malignant Neoplasm of Lung 26 74
Alveolar Cell Carcinoma 76 30
Carcinoma of Lung 12 74
Lung Neoplasms 26 74
Lung Neoplasm 12 77
Nsclc 12 56
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 58
Nonsmall Cell Lung Cancer, Susceptibility to 58
Nonsmall Cell Lung Cancer, Somatic 58
Primary Malignant Neoplasm of Lung 74
Bronchioloalveolar Adenocarcinoma 74
Adenocarcinoma of Lung, Somatic 58
Carcinoma, Non-Small-Cell Lung 45
Lung Non-Small Cell Carcinoma 12
Carcinoma Non-Small Cell Lung 56
Cancer, Lung, Non-Small Cell 41
Lung Cancer, Resistance to 58
Malignant Tumor of Lung 26
Adenocarcinoma of Lung 76
Lung Malignant Tumors 26
Respiratory Carcinoma 26
Lung Cancer, Somatic 58
Malignant Lung Tumor 26
Pulmonary Carcinoma 26
Pulmonary Neoplasms 26
Cancer of Bronchus 26
Cancer of the Lung 26
Lung Malignancies 26
Pulmonary Cancer 26
Neoplasm of Lung 30
Cancer of Lung 12
Cancer, Lung 41
Cancer Lung 56
Lncr 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genes associated with susceptibility to lung cancer, e.g., faslg , fas , chrna5 , chrna3
genes associated with a protection against lung cancer, e.g., casp8 , cyp2a6
mutations in egfr (131550) are associated with altered response to treatment with tyrosine kinase inhibitors



Classifications:



Summaries for Lung Cancer

MedlinePlus : 44 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung cancer, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Alimta and Keytruda have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are alveolar cell carcinoma and Decreased viability

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Genetics Home Reference : 26 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

OMIM : 58 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the lungs, it is called lung cancer. Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

UniProtKB/Swiss-Prot : 76 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 77 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1126)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 36.1 AKT1 ALK BRAF CASP8 EGFR ERBB2
2 small cell cancer of the lung 35.3 AKT1 EGFR KIT PIK3CA PTEN
3 adenosquamous lung carcinoma 35.1 ALK EGFR ERBB2 KRAS PIK3CA
4 lung squamous cell carcinoma 34.5 AKT1 ALK BRAF EGFR KRAS PIK3CA
5 lung adenoid cystic carcinoma 33.9 ALK KIT KRAS PIK3CA
6 adenocarcinoma 33.3 AKT1 ALK BRAF EGFR ERBB2 KIT
7 breast cancer 33.0 AKT1 ALK BRAF CASP8 EGFR ERBB2
8 colorectal cancer 32.8 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
9 squamous cell carcinoma 32.5 AKT1 BRAF EGFR ERBB2 PIK3CA PTEN
10 ovarian cancer 32.3 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
11 esophageal cancer 32.1 AKT1 CASP8 EGFR ERBB2 FASLG KRAS
12 hepatocellular carcinoma 32.1 AKT1 CASP8 EGFR FASLG KRAS MAP2K1
13 glioblastoma 32.0 AKT1 ALK BRAF EGFR ERBB2 NRAS
14 gastric cancer 32.0 AKT1 EGFR ERBB2 IRF1 KRAS PIK3CA
15 thyroid cancer 32.0 AKT1 BRAF EGFR KIT KRAS MAP2K1
16 prostate cancer 31.9 AKT1 CASP8 EGFR ERBB2 KRAS MAP2K1
17 gastric adenocarcinoma 31.9 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
18 small cell carcinoma 31.8 EGFR KIT PTEN
19 myeloma, multiple 31.7 AKT1 BRAF CASP8 KIT KRAS NRAS
20 glioma 31.6 BRAF EGFR ERBB2 PIK3CA PTEN
21 breast adenocarcinoma 31.6 AKT1 CASP8 EGFR ERBB2 KRAS PIK3CA
22 squamous cell carcinoma, head and neck 31.6 AKT1 BRAF EGFR ERBB2 PIK3CA PTEN
23 cervical cancer 31.5 AKT1 CASP8 ERBB2 IRF1 PIK3CA PPP2R1B
24 pancreatic cancer 31.5 PIK3CA MAP2K1 KRAS ERBB2 EGFR AKT1
25 gastrointestinal stromal tumor 31.5 AKT1 BRAF EGFR KIT KRAS PTEN
26 autoimmune lymphoproliferative syndrome 31.5 CASP8 FASLG KRAS NRAS
27 glioblastoma multiforme 31.4 AKT1 EGFR ERBB2 PIK3CA PTEN
28 undifferentiated pleomorphic sarcoma 31.4 KIT KRAS PIK3CA
29 lymphoma, non-hodgkin, familial 31.4 ALK BRAF CASP8 NRAS PIK3CA
30 carcinosarcoma 31.4 ERBB2 KIT KRAS PIK3CA PTEN
31 adenoid cystic carcinoma 31.4 AKT1 ERBB2 KIT KRAS PIK3CA PTEN
32 adenosquamous carcinoma 31.3 EGFR KIT KRAS PIK3CA
33 bladder urothelial carcinoma 31.3 AKT1 BRAF ERBB2 KIT KRAS MAP2K1
34 endometrial cancer 31.3 AKT1 BRAF EGFR ERBB2 KIT KRAS
35 cardiofaciocutaneous syndrome 1 31.3 BRAF KRAS MAP2K1
36 leukemia, acute myeloid 31.3 AKT1 CASP8 KIT KRAS NRAS
37 ovarian cancer 1 31.3 AKT1 ERBB2 KRAS PIK3CA
38 cholangiocarcinoma 31.2 AKT1 BRAF EGFR ERBB2 KRAS PIK3CA
39 transitional cell carcinoma 31.2 BRAF EGFR ERBB2 PTEN
40 renal cell carcinoma, papillary, 1 31.1 BRAF ERBB2 KIT NRAS PIK3CA PTEN
41 suppression of tumorigenicity 12 31.1 AKT1 BRAF PIK3CA PTEN
42 uterine carcinosarcoma 31.0 EGFR ERBB2 KIT PIK3CA PTEN
43 gallbladder cancer 31.0 AKT1 EGFR ERBB2 KRAS PIK3CA
44 estrogen-receptor positive breast cancer 30.9 AKT1 EGFR ERBB2 PIK3CA
45 langerhans cell histiocytosis 30.9 BRAF MAP2K1 NRAS
46 leukemia, chronic lymphocytic 2 30.8 BRAF KRAS NRAS
47 mucinous adenocarcinoma 30.7 ALK EGFR KRAS
48 ovary adenocarcinoma 30.7 ERBB2 KRAS PIK3CA
49 lymphoproliferative syndrome 30.7 CASP8 FASLG NRAS
50 colorectal adenocarcinoma 30.6 BRAF EGFR KRAS

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Human phenotypes related to Lung Cancer:

33
# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 33 HP:0006519

Symptoms via clinical synopsis from OMIM:

58
Respiratory Lung:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Neoplasia:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Clinical features from OMIM:

211980

UMLS symptoms related to Lung Cancer:


fever, dyspnea, hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

27 (show top 50) (show all 93)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.22 BRAF KRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.22 KRAS
3 Decreased viability GR00107-A-1 11.22 MAP2K1
4 Decreased viability GR00221-A-1 11.22 KIT KRAS EGFR PIK3CA AKT1 NRAS
5 Decreased viability GR00221-A-2 11.22 KRAS MAP3K8 PIK3CA AKT1
6 Decreased viability GR00221-A-3 11.22 MAP3K8 AKT1 ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.22 BRAF MAP3K8 EGFR PIK3CA AKT1 ERBB2
8 Decreased viability GR00301-A 11.22 BRAF KIT KRAS MAP3K8
9 Decreased viability GR00342-S-1 11.22 MAP3K8 MAP2K1
10 Decreased viability GR00342-S-2 11.22 MAP3K8 MAP2K1
11 Decreased viability GR00342-S-3 11.22 MAP3K8 MAP2K1
12 Decreased viability GR00381-A-1 11.22 BRAF KRAS
13 Decreased viability GR00402-S-2 11.22 BRAF KIT KRAS MAP3K8 EGFR PIK3CA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.8 PRKN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.8 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.8 CYP2A6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.8 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.8 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.8 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.8 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.8 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.8 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.8 IRF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.8 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.8 IRF1 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.8 PIK3CA KIT
27 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.8 IRF1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.8 AKT1 PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.8 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.8 ERBB2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.8 BRAF PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.8 KRAS ERBB2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.8 KIT PRKN
34 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.8 CYP2A6
35 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.8 AKT1 BRAF CYP2A6 KRAS PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.8 PIK3CA EGFR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.8 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.8 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.8 PRKN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.8 PRKN
41 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.8 ERBB2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.8 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.8 EGFR
44 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.8 KRAS
45 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.8 BRAF IRF1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.8 KIT
47 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.8 BRAF
48 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.8 BRAF ERBB2 IRF1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.8 CYP2A6 PRKN
50 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.8 AKT1 PIK3CA KIT

MGI Mouse Phenotypes related to Lung Cancer:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
2 cardiovascular system MP:0005385 10.5 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
3 homeostasis/metabolism MP:0005376 10.49 AKT1 ALK BRAF CASP8 EGFR ERBB2
4 growth/size/body region MP:0005378 10.46 AKT1 ALK BRAF CASP8 EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.44 AKT1 ALK BRAF CASP8 EGFR ERBB2
6 integument MP:0010771 10.44 AKT1 ALK BRAF CASP8 EGFR ERBB2
7 mortality/aging MP:0010768 10.42 AKT1 ALK BRAF CASP8 EGFR ERBB2
8 behavior/neurological MP:0005386 10.37 AKT1 ALK BRAF ERBB2 ERCC6 KIT
9 immune system MP:0005387 10.36 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
10 neoplasm MP:0002006 10.36 AKT1 ALK BRAF CASP8 EGFR ERBB2
11 hematopoietic system MP:0005397 10.35 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
12 embryo MP:0005380 10.34 AKT1 BRAF CASP8 EGFR ERBB2 KIT
13 digestive/alimentary MP:0005381 10.3 BRAF EGFR ERBB2 FASLG KIT KRAS
14 nervous system MP:0003631 10.28 AKT1 ALK BRAF CASP8 EGFR ERBB2
15 muscle MP:0005369 10.22 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
16 liver/biliary system MP:0005370 10.21 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
17 normal MP:0002873 10.18 AKT1 BRAF EGFR ERBB2 FASLG IRF1
18 craniofacial MP:0005382 10.16 BRAF EGFR ERBB2 KIT KRAS MAP2K1
19 limbs/digits/tail MP:0005371 10.13 BRAF EGFR ERBB2 ERCC6 KIT KRAS
20 hearing/vestibular/ear MP:0005377 10.05 BRAF EGFR ERCC6 KIT KRAS MAP2K1
21 reproductive system MP:0005389 10.03 AKT1 ALK BRAF EGFR ERBB2 FASLG
22 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KIT
23 pigmentation MP:0001186 9.91 ALK BRAF EGFR KIT KRAS NRAS
24 respiratory system MP:0005388 9.9 AKT1 ALK BRAF CASP8 EGFR ERBB2
25 skeleton MP:0005390 9.83 AKT1 ALK BRAF EGFR ERBB2 ERCC6
26 vision/eye MP:0005391 9.36 ALK BRAF EGFR ERCC6 FASLG KIT

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 10)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Alimta 19 50 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
2
Keytruda 19 50 PEMBROLIZUMAB Merck September 2014
3
Abraxane 19 PACLITAXEL Celgene October 2012
4
Alecensa 19 ALECTINIB HYDROCHLORIDE Roche December 2015
5
Iressa 19 GEFITINIB AstraZeneca May 2003
6
Opdivo 19 NIVOLUMAB Bristol-Myers Squibb March 2015
7
Portazza 19 NECITUMUMAB Eli Lilly November 2015
8
Tagrisso 19 OSIMERTINIB MESYLATE AstraZeneca November 2015
9
Xalkori 19 CRIZOTINIB Pfizer August of 2011
10
Zykadia 19 CERITINIB Novartis April 2014

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1060)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 5281004 63006
2
Ipratropium Approved, Experimental Phase 4,Not Applicable 22254-24-6, 60205-81-4 657309 43232
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 143 6006
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
10
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
13
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
14
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
15
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
16
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
17
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
18
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
19
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
22
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
23
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
24
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 44424639 60780
25
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
26
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
27
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 5284616 6436030
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
30
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 70789204 6442177
31
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
32
afatinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850140-72-6, 439081-18-2 10184653
33
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
34
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
35
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95734-82-0
36
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 175805 71273
37
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
38
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
40
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20537-88-6 2141
41
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 89594 942
42
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
43
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
44
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
45
Atezolizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1380723-44-3
46
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
47
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
49
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 6918365 151165
50
Ondansetron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595

Interventional clinical trials:

(show top 50) (show all 7379)
# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
6 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
7 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
8 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
9 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
10 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
13 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
14 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
15 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
16 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
17 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
18 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
19 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
20 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
21 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
22 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
23 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
24 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
25 Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
26 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
27 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
28 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
29 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
30 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
31 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
32 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
33 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
34 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
35 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
36 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
37 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
38 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
39 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
40 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
41 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
42 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
43 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
44 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
45 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
46 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
47 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
48 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
49 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
50 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 30
2 Lung Cancer 30 BRAF CASP8 CYP2A6 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA PPP2R1B PRKN SLC22A18
3 Lung Cancer, Protection Against 30
4 Alveolar Cell Carcinoma 30
5 Neoplasm of Lung 30

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

42
Lung, Brain, Breast, Testes, T Cells, Lymph Node, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

20
The Lung

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 26930)
# Title Authors Year
1
Ovine Pulmonary Adenocarcinoma: A Unique Model to Improve Lung Cancer Research. ( 31106157 )
2019
2
Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum. ( 31063863 )
2019
3
The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer. ( 30896637 )
2019
4
Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma. ( 30900377 )
2019
5
Diagnosis of Combined Adenocarcinoma Small Cell Lung Cancer By Endobronchial Ultrasound Transbronchial Needle Aspiration. ( 30908396 )
2019
6
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. ( 30799776 )
2019
7
Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma. ( 30673302 )
2019
8
Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. ( 30642444 )
2019
9
Advanced Lung Cancer Inflammation Index Predicts Outcomes of Patients with Pathological Stage IA Lung Adenocarcinoma Following Surgical Resection. ( 30333361 )
2019
10
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. ( 30282880 )
2019
11
p53-suppressed oncogene TET1 prevents cellular aging in lung cancer. ( 30622117 )
2019
12
Amenorrhea after lung cancer treatment. ( 30153217 )
2019
13
Tracheobronchial Amyloidosis as an Incidental Finding in a Patient With Lung Cancer. ( 30683519 )
2019
14
Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. ( 30659040 )
2019
15
The Effects of Dietary Supplements on Asthma and Lung Cancer Risk in Smokers and Non-Smokers: A Review of the Literature. ( 30925812 )
2019
16
Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression. ( 31100307 )
2019
17
Can Local Infiltration of Lidocaine Reduce the Postoperative Atrial Fibrillation Rate in Patients undergoing Lobectomy for Lung Cancer? ( 31010387 )
2019
18
Impact of atrial fibrillation in patients with lung cancer: Insights from National Inpatient Sample. ( 30963100 )
2019
19
Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. ( 30680206 )
2019
20
Yonder: Traumatic brain injury, lung cancer, bariatric surgery, and screen time. ( 30923150 )
2019
21
Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. ( 30993450 )
2019
22
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. ( 30925779 )
2019
23
Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projections may not reveal the full picture. ( 30840327 )
2019
24
A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer. ( 30799393 )
2019
25
Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab. ( 30758879 )
2019
26
A case of cancer-associated retinopathy with chorioretinitis and optic neuritis associated with occult small cell lung cancer. ( 31046716 )
2019
27
Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. ( 30727791 )
2019
28
The biomarkers and potential pathogenesis of lung cancer related cerebral hemorrhage. ( 31096511 )
2019
29
Abscopal Resolution of a Hepatic Metastasis in a Patient with Metastatic Cholangiocarcinoma Following Radical Stereotactic Body Radiotherapy to a Synchronous Early Stage Non-small Cell Lung Cancer. ( 31019860 )
2019
30
Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. ( 30993095 )
2019
31
The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. ( 30885163 )
2019
32
Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. ( 30568222 )
2019
33
Dispositional mindfulness, self-compassion, and compassion from others as moderators between stress and depression in caregivers of patients with lung cancer. ( 31087458 )
2019
34
New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. ( 31056371 )
2019
35
Depression and Inflammation among Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Patients. ( 31022775 )
2019
36
Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. ( 30779396 )
2019
37
Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients. ( 30568143 )
2019
38
C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. ( 30521079 )
2019
39
Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer. ( 29896926 )
2019
40
Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. ( 30906559 )
2019
41
Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. ( 30210109 )
2019
42
Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis. ( 30706684 )
2019
43
Metformin improves survival in lung cancer patients with type 2 diabetes mellitus: A meta-analysis. ( 30173870 )
2019
44
Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea. ( 30693820 )
2019
45
Role of speech and language therapy in managing dysphagia and dysphonia in lung cancer. ( 31064787 )
2019
46
Self-expandable metal stent for dysphagia caused by mediastinal masses in patients with lung cancer. ( 30733178 )
2019
47
Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. ( 30850565 )
2019
48
Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. ( 30953906 )
2019
49
Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. ( 30619952 )
2019
50
Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. ( 31110718 )
2019